RESULTS OF A PHASE 2 STUDY OF RG6125, AN ANTI-CADHERIN-11 MONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO ANTI-TNFALPHA THERAPY

被引：17
|
作者：
Finch, Rebecca [1 ]
Sostelly, Alexandre [2 ]
Sue-Ling, Kim [3 ]
Blaeuer, Angela [2 ]
Duchateau-Nguyen, Guillemette [2 ]
Ukarma, Lidia [2 ]
Petry, Claire [2 ]
Ravva, Patanjali [2 ]
Villiger, Peter [4 ]
Junker, Uwe [2 ]
机构：
[1] Roche Prod Ltd, Welwyn Garden City, England
[2] Roche Innovat Ctr Basel, Basel, Switzerland
[3] Roche Innovat Ctr New York, New York, NY USA
[4] Inselspital Bern, Bern, Switzerland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
D O I：
10.1136/annrheumdis-2019-eular.3028
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0224
引用
收藏
页码：189 / 189
页数：1
相关论文
共 50 条
  • [41] Anti TNFα antibody (cA2) therapy in rheumatoid arthritis:: Rationale, clinical results and mechanism of action
    Feldmann, M
    Brennan, F
    Paleolog, E
    Taylor, P
    Maini, R
    EUROPEAN CYTOKINE NETWORK, 1998, 9 (03) : 366 - 366
  • [42] A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis
    Haringman, Jasper J.
    Gerlag, Danielle M.
    Smeets, Tom J. M.
    Baeten, Dominique
    Van den Bosch, Filip
    Bresnihan, Barry
    Breedveld, Ferdinand C.
    Dinant, Huib J.
    Legay, Francois
    Gram, Hermann
    Loetscher, Pius
    Schmouder, Robert
    Woodworth, Thasia
    Tak, Paul P.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (08): : 2387 - 2392
  • [43] Sustained improvements through 18 months with abatacept in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy.
    Genovese, M
    Luggen, M
    Schiff, M
    Sherrer, Y
    Sen, K
    Aranda, R
    Beckers, JC
    Dougados, M
    ARTHRITIS AND RHEUMATISM, 2005, 52 (12): : 4064 - 4064
  • [44] A PHASE IIB STUDY OF THE EFFICACY AND SAFETY OF SUBCUTANEOUS CLAZAKIZUMAB (ANTI-IL-6 MONOCLONAL ANTIBODY) WITH OR WITHOUT METHOTREXATE IN ADULTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO METHOTREXATE
    Weinblatt, M.
    Mease, P.
    Mysler, E.
    Takeuchi, T.
    Drescher, E.
    Berman, A.
    Zilberstein, M.
    Xing, J.
    Emery, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 680 - 681
  • [45] A Phase IIb Study Of The Efficacy and Safety Of Subcutaneous Clazakizumab (anti-IL-6 monoclonal antibody) With Or Without Methotrexate In Adults With Moderate-To-Severe Active Rheumatoid Arthritis and An Inadequate Response To Methotrexate
    Weinblatt, M.
    Mease, P.
    Mysler, E.
    Takeuchi, T.
    Drescher, E.
    Berman, A.
    Zilberstein, M.
    Xing, J.
    Emery, P.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S735 - S736
  • [46] A PHASE 2 STUDY OF MULTIPLE SUBCUTANEOUS DOSES OF LY2439821, AN ANTI-IL-17 MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS IN TWO POPULATIONS: NAIVE TO BIOLOGIC THERAPY OR INADEQUATE RESPONDERS TO TUMOR NECROSIS FACTOR ALPHA INHIBITORS
    Genovese, M.
    Greenwald, M.
    Cho, C. -S.
    Berman, A.
    Jin, L.
    Cameron, G.
    Wang, L.
    Xie, L.
    Braun, D.
    Berclaz, P. -Y.
    Banerjee, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 59 - 59
  • [47] Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study
    Taylor, Peter C.
    Keystone, Edward C.
    van der Heijde, D.
    Tanaka, Yoshiya
    Ishii, Taeko
    Emoto, Kahaku
    Yang, Lili
    Arora, Vipin
    Gaich, Carol L.
    Rooney, Terence
    Schlichting, Douglas E.
    Macias, William
    de Bono, Stephanie
    Weinblatt, Michael E.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [48] Baricitinib vs. placebo or adalimumab in patients with active rheumatoid arthritis and an inadequate response to background methotrexate therapy: results of a phase 3 study
    Taylor, P.
    Keystone, E. C.
    van der Heijde, D.
    Tanaka, Y.
    Ishii, T.
    Emoto, K.
    Yang, L.
    Arora, V.
    Gaich, C.
    Rooney, T.
    Schlichting, D.
    Macias, W. L.
    De Bono, S.
    Weinblatt, M. E.
    Larsson, E.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2016, 45 : 8 - 8
  • [49] A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy
    Kremer, Joel M.
    Emery, Paul
    Camp, Heidi S.
    Friedman, Alan
    Wang, Li
    Othman, Ahmed A.
    Khan, Nasser
    Pangan, Aileen L.
    Jungerwirth, Steven
    Keystone, Edward C.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68 (12) : 2867 - 2877
  • [50] First in Human Study with Recombinant Anti-IL-21 Monoclonal Antibody in Healthy Subjects and Patients with Rheumatoid Arthritis
    Ignatenko, Stanislav
    Skrumsager, Birte K.
    Steensberg, Adam
    Mouritzen, Ulrik
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S547 - S547
12345